




The relative strengths and weaknesses of Sarepta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 23% points. The greatest weakness of Sarepta Therapeutics Inc is the variable Net Income, reducing the Economic Capital Ratio by 42% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 26% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	224,543
Cost of Goods Sold	0
Intangible Assets	6,642
Liabilities, Current	62,294
Liabilities, Non-Current	6,172
Other Assets	5,253
Other Compr. Net Income	-16
Other Expenses	0
Other Liabilities	14,969
Other Net Income	1,407
Other Revenues	0
Property and Equipment	37,344
Research and Development	146,394
Selling, General and Administrative Expense	75,043

Output Variable	Value in 1000 USD
Assets	273,782
Liabilities	83,435
Expenses	221,437
Revenues	0
Stockholders Equity	190,347
Net Income	-220,030
Comprehensive Net Income	-220,038
BaseVar	290,038
ECR before Limited Liability	109%
Economic Capital Ratio	237%